Healthcare Featured

Three Companies Decide What Your Prescriptions Cost

They aren't drug makers and they aren't quite your insurer. Three vertically integrated middlemen control 80% of US prescriptions and the opaque pricing that keeps costs high. In 2026, the FTC, Congress, and the states all turned on the lights at once.

Alpha One

06 Jul 2026 • 7 min read

Every time you hand over a prescription, three companies you never chose — and probably can't name — decide what it costs. They aren't drug manufacturers. They aren't your insurer, exactly. They are pharmacy benefit managers, the middlemen who sit between the pill and your wallet, and together they control roughly 80% of every prescription filled in America.

For twenty years that arrangement was invisible by design. In 2026 it stopped being invisible. A federal antitrust case, a new federal law, and a wave of state bans have all landed on the same target inside twelve months — and the most profitable, least understood corner of the American health system is being pried open in public. Here is who these companies are, how they make money, and why the repricing matters for anyone who owns a health insurer.

The three companies

The industry calls them the "Big Three," and the concentration is not a rounding error:

Express Scripts — owned by Cigna (through its Evernorth arm) — roughly 31% of US prescriptions.
CVS Caremark — owned by CVS Health — roughly 26%.
OptumRx — owned by UnitedHealth Group — roughly 23%.

Add them up and about 80 cents of every prescription dollar in the country flows through three corporate parents. That share has barely moved in years, despite scrutiny, client defections, and a parade of would-be disruptors.

What makes the position so durable is not the PBM business alone — it's what sits around it. Each of the three is vertically integrated to a degree that would make a Gilded Age industrialist blush. UnitedHealth owns OptumRx (the PBM), UnitedHealthcare (the insurer), and Optum's own pharmacies and data operation. CVS owns Caremark (the PBM), Aetna (the insurer), and the retail and specialty pharmacies where the drugs are dispensed. Cigna pairs Express Scripts with its Cigna Healthcare insurance arm. In each case the same corporate parent can collect on the insurance premium, negotiate the drug's price, decide which drugs your plan covers, and then fill the prescription at a pharmacy it owns. The money changes hands several times without ever leaving the building.

How the money actually gets made

A PBM's official job is to negotiate lower drug prices on behalf of employers and health plans. The reality is more lucrative, and it runs on two mechanisms most patients have never heard of.

The first is rebates. Drug manufacturers pay PBMs to secure favorable placement on a plan's formulary — the list of which drugs are covered and at what tier. The larger the rebate a manufacturer offers, the better its placement. That sounds like a discount, but it creates a perverse incentive: a PBM can earn more by favoring a drug with a high list price and a big rebate than a cheaper drug with no rebate. The list price — the number that determines what an uninsured or high-deductible patient pays at the counter — stays inflated on purpose. The FTC's own case argues this is exactly what happened with insulin, where list prices ballooned while the rebates flowed to the middlemen.

The second is spread pricing. The PBM charges the health plan one price for a drug, reimburses the pharmacy a lower price, and pockets the difference — the "spread." The plan doesn't see the pharmacy's number; the pharmacy doesn't see the plan's. Only the PBM sees both. Industry-wide, spread pricing is estimated to pull in around $6 billion a year, concentrated in generic drugs where the gaps are widest.

Neither mechanism is illegal. Both are opaque. And the scale is what turns a modest margin into an empire: PBM gross margins run only about 5% to 8% on the spend they manage, but the spend is measured in hundreds of billions. One analysis put Big Three PBM profits at $6.3 billion in 2012 and $27.6 billion a decade later — a 438% increase over ten years.

Briefings like this land in members' inboxes before the market prices them in. Join free →

2026: the year the cover came off

For most of their history, PBMs were protected by complexity. Nobody could regulate what nobody could see. That protection broke this year on three fronts at once.

The antitrust front. The Federal Trade Commission sued all three PBMs in September 2024, accusing them of using the rebate system to artificially inflate insulin prices and steer patients away from cheaper options. In 2026 the dominoes fell: a landmark settlement with Express Scripts on February 4 — projected to cut patient out-of-pocket costs by as much as $7 billion over ten years — followed by a proposed CVS Caremark settlement in March and reported progress toward an OptumRx deal by mid-June. When the PBMs tried to countersue the FTC, the Eighth Circuit dismissed the effort in early July. The message from Washington is that the rebate machine is now a liability, not a moat.

The legislative front. The Consolidated Appropriations Act of 2026, signed on February 3, does something the antitrust case can't: it rewires the incentives directly. Starting in 2028, PBM compensation in Medicare Part D must be "delinked" from drug prices — paid as flat service fees rather than as a cut of rebates or spread. PBMs will have to pass 100% of manufacturer rebates through to plans (Part D in 2028, commercial plans by 2029), and file semiannual transparency reports on spread, rebates, and their own affiliated-pharmacy activity. Delinking is the quiet revolution here: if a PBM can no longer earn more by choosing the pricier drug, the entire logic of the inflated list price starts to collapse.

The state front. While Washington moved, the states moved faster and harder. All 50 now regulate PBMs in some form. California's SB 41 banned spread pricing in new contracts as of January 1, 2026. Illinois did the same. Colorado went further and pushed toward outright delinking. Kansas, Nebraska, Iowa, Montana, Vermont and others have enacted spread bans or pass-through mandates, many paired with minimum pharmacy reimbursement floors to keep independent pharmacies alive.

What it means for your money

The instinct is to read this as a simple short on CVS, Cigna, and UnitedHealth. It isn't that clean, and the nuance is where the actual signal lives.

Start with what's genuinely at risk. Spread and rebate economics are the highest-margin, lowest-visibility profits inside these conglomerates — and they are being targeted precisely because they are opaque. Delinking and mandatory pass-through don't trim that profit pool; they remove the mechanism that generates it. For businesses whose insurance arms are already under pressure from rising medical costs, losing the PBM's hidden margin engine is not a rounding error.

Now the reasons it's a bleed, not a cliff. The federal delinking rules phase in over 2028 and 2029, which gives the incumbents years to adapt — and they are already adapting. CVS has rolled out a "TrueCost" transparent-pricing model; expect flat-fee, pass-through offerings from all three, repackaging the same vertical integration in a form regulators will accept. The 80% share is sticky because switching a PBM is operationally painful for large employers. This is margin compression on a delay, not a sudden collapse — and the market tends to misprice slow bleeds in both directions.

Then watch the disruptors, because they are the tell. Mark Cuban's Cost Plus Drugs publishes its acquisition cost, adds a flat 15% markup and a small pharmacist fee, and simply refuses to play the spread game — a direct assault on the generic-drug margins where the Big Three make their easiest money. Transparent, fiduciary-aligned PBMs like SmithRx and Navitus, plus Amazon Pharmacy, are taking small but accelerating share as employers, newly armed with transparency reports, start asking questions they couldn't ask before. None of them threatens 80% dominance yet. But they set the ceiling on how much longer opacity can be sold as a product.

The through-line: for two decades, the profitable thing about America's drug supply chain was that no one could see how it worked. In 2026, the law, the courts, and the states all decided to turn on the lights at the same time. The companies standing in that light have spent years earning a margin that was invisible on purpose. The repricing of that margin — how fast, how deep, and who captures the share it sheds — is one of the more underfollowed stories in healthcare. Now you know where to look.

If this analysis was useful, this is what AlphaBriefing does every day — geopolitics and markets, connected to what it means for your money. Free members get the daily brief in their inbox; paid members get the investment frameworks, scenario pricing, and catalyst calendars behind the paywall.

Get this level of intelligence every day. Subscribe to AlphaBriefing — free, member, and paid tiers available.

Sources & Further Reading

Disclaimer

AlphaBriefing is an independent intelligence publication. The content in this article is produced for informational and educational purposes only. Nothing published by AlphaBriefing constitutes financial, investment, legal, tax, or regulatory advice, nor should it be construed as a solicitation or recommendation to buy, sell, or hold any security, asset, or financial instrument.

All views expressed are those of the author at the time of writing and are subject to change without notice. Markets are volatile and unpredictable; past performance is not indicative of future results. Any investment involves risk, including the possible loss of principal.

AlphaBriefing and its principals, employees, or contributors may hold positions in securities or assets mentioned in this article. This should be considered a potential conflict of interest. No material relationship with any company referenced exists unless explicitly disclosed. Readers should conduct their own due diligence and consult qualified financial, legal, and tax advisors before making any investment decisions.

Information in this article is drawn from public sources believed to be reliable at the time of publication. AlphaBriefing makes no warranty, express or implied, as to the accuracy, completeness, or timeliness of any information herein. AlphaBriefing accepts no liability for any loss or damage arising from reliance on this content.